Literature DB >> 9238031

Proviral insertions induce the expression of bone-specific isoforms of PEBP2alphaA (CBFA1): evidence for a new myc collaborating oncogene.

M Stewart1, A Terry, M Hu, M O'Hara, K Blyth, E Baxter, E Cameron, D E Onions, J C Neil.   

Abstract

The til-1 locus was identified as a common retroviral integration site in virus-accelerated lymphomas of CD2-myc transgenic mice. We now show that viral insertions at til-1 lead to transcriptional activation of PEBP2alphaA (CBFA1), a transcription factor related to the Drosophila segmentation gene product, Runt. Insertions are upstream and in the opposite orientation to the gene and appear to activate a variant promoter that is normally silent in T cells. Activity of this promoter was detected in rodent osteogenic sarcoma cells and primary osteoblasts, implicating bone as the normal site of promoter activity. The isoforms encoded by the activated gene all encompass the conserved runt DNA-binding domain and share a novel N terminus different from the previously reported PEBP2alphaA products. Minor products include isoforms with internal deletions due to exon skipping and a novel C-terminal domain unrelated to known runt domain factors. The major isoform expressed from the activated til-1 locus (G1) was found to account for virtually all of the core binding factor activity in nuclear extracts from its corresponding lymphoma cell line. Another member of this gene family, AML1(CBFA2), is well known for its involvement in human hemopoietic tumors. These results provide evidence of a direct oncogenic role for PEBP2alphaA and indicate that the Myc and Runt family genes can cooperate in oncogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9238031      PMCID: PMC23059          DOI: 10.1073/pnas.94.16.8646

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Comparison of the human genomic structure of the Runt domain-encoding PEBP2/CBFalpha gene family.

Authors:  M Y Ahn; S C Bae; M Maruyama; Y Ito
Journal:  Gene       Date:  1996-02-12       Impact factor: 3.688

2.  Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies.

Authors:  M Kurokawa; T Tanaka; K Tanaka; S Ogawa; K Mitani; Y Yazaki; H Hirai
Journal:  Oncogene       Date:  1996-02-15       Impact factor: 9.867

3.  The tissue-specific nuclear matrix protein, NMP-2, is a member of the AML/CBF/PEBP2/runt domain transcription factor family: interactions with the osteocalcin gene promoter.

Authors:  H L Merriman; A J van Wijnen; S Hiebert; J P Bidwell; E Fey; J Lian; J Stein; G S Stein
Journal:  Biochemistry       Date:  1995-10-10       Impact factor: 3.162

4.  Moloney murine leukemia virus-induced lymphomas in p53-deficient mice: overlapping pathways in tumor development?

Authors:  E W Baxter; K Blyth; L A Donehower; E R Cameron; D E Onions; J C Neil
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

5.  Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.

Authors:  C Zent; N Kim; S Hiebert; D E Zhang; D G Tenen; J D Rowley; G Nucifora
Journal:  Curr Top Microbiol Immunol       Date:  1996       Impact factor: 4.291

6.  Molecular cloning and characterization of PEBP2 beta, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2 alpha.

Authors:  E Ogawa; M Inuzuka; M Maruyama; M Satake; M Naito-Fujimoto; Y Ito; K Shigesada
Journal:  Virology       Date:  1993-05       Impact factor: 3.616

7.  A PEBP2 alpha/AML-1-related factor increases osteocalcin promoter activity through its binding to an osteoblast-specific cis-acting element.

Authors:  V Geoffroy; P Ducy; G Karsenty
Journal:  J Biol Chem       Date:  1995-12-29       Impact factor: 5.157

8.  Transactivation of the Moloney murine leukemia virus and T-cell receptor beta-chain enhancers by cbf and ets requires intact binding sites for both proteins.

Authors:  W Sun; B J Graves; N A Speck
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

9.  til-1: a novel proviral insertion locus for Moloney murine leukaemia virus in lymphomas of CD2-myc transgenic mice.

Authors:  M Stewart; A Terry; M O'Hara; E Cameron; D Onions; J C Neil
Journal:  J Gen Virol       Date:  1996-03       Impact factor: 3.891

10.  Expression of runtB is modulated during chondrocyte differentiation.

Authors:  P Castagnola; M Gennari; A Gaggero; F Rossi; A Daga; M T Corsetti; F Calabi; R Cancedda
Journal:  Exp Cell Res       Date:  1996-03-15       Impact factor: 3.905

View more
  55 in total

1.  Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1).

Authors:  T L Gu; T L Goetz; B J Graves; N A Speck
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

2.  Subnuclear targeting of Runx/Cbfa/AML factors is essential for tissue-specific differentiation during embryonic development.

Authors:  J Y Choi; J Pratap; A Javed; S K Zaidi; L Xing; E Balint; S Dalamangas; B Boyce; A J van Wijnen; J B Lian; J L Stein; S N Jones; G S Stein
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

3.  Co-stimulation of the bone-related Runx2 P1 promoter in mesenchymal cells by SP1 and ETS transcription factors at polymorphic purine-rich DNA sequences (Y-repeats).

Authors:  Ying Zhang; Mohammad Q Hassan; Rong-Lin Xie; John R Hawse; Thomas C Spelsberg; Martin Montecino; Janet L Stein; Jane B Lian; Andre J van Wijnen; Gary S Stein
Journal:  J Biol Chem       Date:  2008-11-18       Impact factor: 5.157

4.  Runx2 protein expression utilizes the Runx2 P1 promoter to establish osteoprogenitor cell number for normal bone formation.

Authors:  Julie C Liu; Christopher J Lengner; Tripti Gaur; Yang Lou; Sadiq Hussain; Marci D Jones; Brent Borodic; Jennifer L Colby; Heather A Steinman; Andre J van Wijnen; Janet L Stein; Stephen N Jones; Gary S Stein; Jane B Lian
Journal:  J Biol Chem       Date:  2011-06-15       Impact factor: 5.157

5.  Continuous expression of Cbfa1 in nonhypertrophic chondrocytes uncovers its ability to induce hypertrophic chondrocyte differentiation and partially rescues Cbfa1-deficient mice.

Authors:  S Takeda; J P Bonnamy; M J Owen; P Ducy; G Karsenty
Journal:  Genes Dev       Date:  2001-02-15       Impact factor: 11.361

6.  Runx2 induces acute myeloid leukemia in cooperation with Cbfbeta-SMMHC in mice.

Authors:  Ya-Huei Kuo; Sayyed K Zaidi; Svetlana Gornostaeva; Toshihisa Komori; Gary S Stein; Lucio H Castilla
Journal:  Blood       Date:  2009-01-28       Impact factor: 22.113

7.  Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival.

Authors:  S Wotton; A Terry; A Kilbey; A Jenkins; P Herzyk; E Cameron; J C Neil
Journal:  Oncogene       Date:  2008-06-16       Impact factor: 9.867

8.  Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma.

Authors:  Xin-Yan Lu; Yaojuan Lu; Yi-Jue Zhao; Kim Jaeweon; Jason Kang; Li Xiao-Nan; Gouqing Ge; Rene Meyer; Laszlo Perlaky; John Hicks; Murali Chintagumpala; Wei-Wen Cai; Marc Ladanyi; Richard Gorlick; Ching C Lau; Debananda Pati; Michael Sheldon; Pulivarthi H Rao
Journal:  Mol Cancer Res       Date:  2008-06       Impact factor: 5.852

9.  Fuzzy clustering analysis of osteosarcoma related genes.

Authors:  Kai Chen; Dajiang Wu; Yushu Bai; Xiaodong Zhu; Ziqiang Chen; Chuanfeng Wang; Yingchuan Zhao; Ming Li
Journal:  Pathol Oncol Res       Date:  2013-11-30       Impact factor: 3.201

10.  Intragenic microdeletion of RUNX2 is a novel mechanism for cleidocranial dysplasia.

Authors:  Ming Ta Michael Lee; Anne Chun-Hui Tsai; Ching-Heng Chou; Feng-Mei Sun; Li-Chen Huang; Pauline Yen; Chyi-Chyang Lin; Chih-Yang Liu; Jer-Yuarn Wu; Yuan-Tsong Chen; Fuu-Jen Tsai
Journal:  Genomic Med       Date:  2008-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.